Madison, NJ, United States
Madison, NJ, United States

Quest Diagnostics Incorporated is a corporation that provides clinical laboratory services. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name in 1997. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico and a laboratory in India and also has collaborative agreements internationally with various hospitals and clinics. It is a member of the Fortune 500 and the S&P 500, with corporate headquarters located in Madison, New Jersey. The company has approximately 43,000 employees, and generates more than $7.5 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders. Wikipedia.


Time filter

Source Type

Patent
Quest Diagnostics | Date: 2017-01-18

Disclosed herein are methods and compositions for detecting one or more pathogens that cause atypical pneumonia. Detectable pathogens include Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.


Patent
Quest Diagnostics | Date: 2017-02-01

Provided are methods for determining the amount of dihydrotestosterone (DHT) in a sample using mass spectrometry. The methods generally involve ionizing DHT in a sample and detecting and quantifying the amount of the ion to determine the amount of DHT in the sample.


Patent
Quest Diagnostics | Date: 2017-02-22

Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5 and 3 regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5 portion of a target gene relative to the 3 region of the target gene.


Patent
Quest Diagnostics | Date: 2016-12-22

Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.


Patent
Quest Diagnostics | Date: 2016-12-22

Provided are methods of detecting the presence or amount of a vitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a vitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. Also provided are methods to detect the presence or amount of two or more vitamin D metabolites in a single assay.


Patent
Quest Diagnostics | Date: 2017-01-09

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.


Provided are methods for determining the amount of tamoxifen and its metabolites in a sample by mass spectrometry. In some aspects, the methods provided herein comprise determining the amount of norendoxifen. In some aspects, the methods provided herein comprise determining the amount of norendoxifen and tamoxifen. In some aspects, the methods provided herein comprise determining the amount of norendoxifen and other tamoxifen metabolites. In some aspects, the methods provided herein comprise determining the amount of tamoxifen, norendoxifen, and other tamoxifen metabolites.


Patent
Quest Diagnostics, Clinical Genomics Pty. Ltd., Pedersen, Lapointe and Baker | Date: 2017-04-12

Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.


Patent
Quest Diagnostics | Date: 2017-03-08

Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.


Patent
Quest Diagnostics | Date: 2016-12-08

Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5 and 3 regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5 portion of a target gene relative to the 3 region of the target gene.

Loading Quest Diagnostics collaborators
Loading Quest Diagnostics collaborators